Evidence mapPaperPMID 40649979Full record

ArticleInternational journal of molecular sciences2025

Identification of Potential Therapeutic Targets for Coronary Atherosclerosis from an Inflammatory Perspective Through Integrated Proteomics and Single-Cell Omics.

Hesong Wang, Fengzhe Xie, Meng Wang, Jianxin Ji, Yongzhen Song, Yanyan Dai, Liuying Wang, Zheng Kang, Lei Cao

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hesong WangDepartment of Biostatistics, School of Public Health, Harbin Medical University, Harbin 150081, China.
Fengzhe XieDepartment of Social Medicine, School of Health Management, Harbin Medical University, Harbin 150081, China.
Meng WangDepartment of Biostatistics, School of Public Health, Harbin Medical University, Harbin 150081, China.
Jianxin JiDepartment of Biostatistics, School of Public Health, Harbin Medical University, Harbin 150081, China.
Yongzhen SongDepartment of Biostatistics, School of Public Health, Harbin Medical University, Harbin 150081, China.
Yanyan DaiDepartment of Biostatistics, School of Public Health, Harbin Medical University, Harbin 150081, China.
Liuying WangDepartment of Social Medicine, School of Health Management, Harbin Medical University, Harbin 150081, China.
Zheng KangDepartment of Social Medicine, School of Health Management, Harbin Medical University, Harbin 150081, China.
Lei CaoDepartment of Biostatistics, School of Public Health, Harbin Medical University, Harbin 150081, China.

Funding

National Natural Science Foundation of China 82273734National Natural Science Foundation of China 82304250
6 · The paper itself

Abstract

Coronary atherosclerosis (CAS) is a major cause of cardiovascular morbidity worldwide. The understanding of atherosclerosis has shifted from a cholesterol deposition disorder to an inflammation-driven disease, with anti-inflammatory therapies demonstrating clinical efficacy. Identifying inflammatory protein targets is crucial for developing targeted therapies. A proteome-wide Mendelian randomization (MR) analysis was performed to explore therapeutic targets for CAS by integrating inflammatory proteomics data from the UK-PPP (54,219 participants, 2923 proteins) and Iceland cohorts (35,559 participants, 4907 proteins) as exposures and outcome data for CAS, atherosclerosis, and carotid atherosclerosis from FinnGen. Replication MR employed meta-analysis of six proteomics datasets and CAS data from three sources, while the impact of the identified proteins on four cardiovascular diseases was also investigated. Colocalization analysis (PPH

Indexed as

Coronary Artery DiseaseInflammationProteomeProteomicsSingle-Cell AnalysisHumansMendelian Randomization AnalysisProteomecardiovascular diseasescoronary atherosclerosisdrug targetMendelian randomizationproteomicssingle-cell

Identifiers

PMID40649979
PMCPMC12250334

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.